Moleculera Labs Company History

Moleculera Labs was founded by Dr. Madeleine Cunningham and Dr. Craig Shimasaki in response to a need for laboratory evidence supporting an underlying biologic root for seemingly unexplained neuropsychiatric symptoms. The company opened its clinical laboratory in April 2013 specifically to meet the testing needs of physicians treating individuals suffering from perplexing autoimmune neuropsychiatric disorders that are treatable.

In 1998, Dr. Cunningham was recruited by the National Institute of Mental Health (NIMH) to help investigate a new disorder (PANDAS) that had been identified in children and resembled Sydenham’s chorea. As a leading researcher, well-versed in rheumatic fever and Sydenham’s chorea, Dr. Cunningham became embedded in studying PANDAS, working in collaboration with Dr. Susan Swedo, Chief of Pediatrics and Developmental Neuroscience Branch at the NIMH. More than a dozen years later that knowledge and research was translated to develop and launch the Cunningham Panel™ of tests.

Who We Are


We are a team of scientists, medical and laboratory professionals, and administrative staff, committed to serving patients and physicians with compassionate care to provide scientific evidence for patients suffering from perplexing neuropsychiatric disorders.

Our overarching goal is to discover and deliver advanced diagnostic testing services for children and adults suffering from treatable autoimmune neuropsychiatric disorders. We continue to collaborate with world-renowned researchers and physicians to better understand these conditions, and further investigate the underlying etiology of autoimmune neurologic disorders.

Our hope and work commitment is to help bring compassionate support to the countless children and families struggling with these debilitating disorders. And, with the correct diagnosis and treatment we believe that, you can see your children shine again!

About Moleculera Labs